{"id":"intranasal-saline-solution-plus-glycerol","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal irritation"},{"rate":null,"effect":"Epistaxis (rare)"},{"rate":null,"effect":"Local discomfort"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=intranasal saline solution plus glycerol","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:16:49.713794+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:17:07.103831+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:16:56.942705+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=intranasal saline solution plus glycerol","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:16:57.730694+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108251/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:16:59.535266+00:00"}},"_dailymed":null,"aiSummary":"Intranasal saline solution plus glycerol, marketed by Unidad de Investigacion en Enfermedades Cronico-Degenerativas, holds a niche position in the therapeutic landscape. The key composition patent expiring in 2028 provides a temporary barrier to generic competition, enhancing the drug's market stability. However, the lack of revenue data and primary trial results poses a significant risk in assessing its commercial viability and therapeutic efficacy.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Saline solution cleanses and irrigates nasal mucosa while glycerol acts as a humectant and osmotic agent, drawing moisture into the nasal tissues and maintaining hydration of the epithelial surface. This combination helps restore normal nasal function, reduce congestion, and support mucosal barrier integrity.","oneSentence":"Intranasal saline solution with glycerol provides osmotic hydration and mucosal moisturization to the nasal passages.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:42.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:17:07.104584+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Nasal congestion and dryness"},{"name":"Nasal mucosa hydration and cleansing"}]},"trialDetails":[{"nctId":"NCT04306354","phase":"PHASE1, PHASE2","title":"Use of Intranasal Oxytocin During Detoxification of Crack Cocaine","status":"UNKNOWN","sponsor":"Pontificia Universidade Católica do Rio Grande do Sul","startDate":"2018-09-15","conditions":"Cocaine Withdrawal, Cocaine Smoking, Cocaine-Related Disorders","enrollment":96},{"nctId":"NCT00754884","phase":"PHASE4","title":"Calcitonin in the Treatment of Fibromyalgia","status":"WITHDRAWN","sponsor":"Unidad de Investigacion en Enfermedades Cronico-Degenerativas","startDate":"2008-10","conditions":"Fibromyalgia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2108251"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nasalub"],"phase":"marketed","status":"active","brandName":"intranasal saline solution plus glycerol","genericName":"intranasal saline solution plus glycerol","companyName":"Unidad de Investigacion en Enfermedades Cronico-Degenerativas","companyId":"unidad-de-investigacion-en-enfermedades-cronico-degenerativas","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:17:07.104584+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}